Literature DB >> 26886386

Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System.

Robert Lerrigo1, Lauren A Beste, Steven L Leipertz, Pamela K Green, Anna S F Lok, Matthew J Kogut, George N Ioannou.   

Abstract

BACKGROUND AND AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) placement is an effective treatment for complications of portal hypertension. We aimed to describe post-TIPS mortality and its predictors in the modern era of covered stents. PATIENTS AND METHODS: We identified patients with cirrhosis who underwent TIPS insertion at Veterans Affairs Healthcare facilities nationally from 2004 to 2014 (n=703), most of which (95%) were performed as elective procedures. We followed patients until the date of death, transplantation, or the end of the observation period.
RESULTS: TIPS recipients had a mean age of 59.3 years (SD 8) and 97% were men. The mean Model for End Stage Liver Disease (MELD) score was 13 (SD 4.8); 47% had hepatitis C virus (HCV) infection, 48% had variceal hemorrhage, and 40% had ascites. During a mean follow-up of 1.72 years (SD 1.9), 57.5% of TIPS recipients died (n=404) and only 5.3% underwent liver transplantation (n=37). The median survival after TIPS was 1.74 years (interquartile range 0.3-4.7). Thirty-day mortality after TIPS was 11.6% [95% confidence interval (CI) 9.4-14.2], 1-year mortality was 40.3% (95% CI 36.7-44.2), and 3-year mortality was 61.9% (95% CI 57.9-66.0). Independent predictors of post-TIPS mortality included medical comorbidity burden, low albumin, HCV infection, and high MELD score (or high international normalized ratio and bilirubin when the components of the MELD score were analyzed individually). TIPS revision was performed at least once in 27.3% of TIPS recipients.
CONCLUSION: TIPS should not be considered simply as a bridge to transplantation. Burden of extra-hepatic comorbidities, HCV infection, and low serum albumin strongly predict post-TIPS mortality in addition to the MELD score.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26886386     DOI: 10.1097/MEG.0000000000000604

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.

Authors:  George N Ioannou; Pamela Green; Elliott Lowy; Elijah J Mun; Kristin Berry
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

2.  Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.

Authors:  George N Ioannou; Pamela Green; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2019-05-28       Impact factor: 25.083

3.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

4.  Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis.

Authors:  George N Ioannou; Weijing Tang; Lauren A Beste; Monica A Tincopa; Grace L Su; Tony Van; Elliot B Tapper; Amit G Singal; Ji Zhu; Akbar K Waljee
Journal:  JAMA Netw Open       Date:  2020-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.